
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses about indirect comparison of biologics for CRSwNP, focusing on clinical outcomes like symptom relief and safety and also highlights dupilumab, omalizumab, and mepolizumab as effective and well-tolerated options.

Prof. Salvatore Oliva and Dr. Milli Gupta discuss the importance of long-term care, multidimensional assessment, and the latest data for biologics.

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

Join Profs. Sachio Takeno and Joaquim Mullol for an educational symposium highlighting the multifaceted burden associated with loss of smell and congestion in patients with uncontrolled CRSwNP.

This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.

Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation

An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.
Dr. Dhandapani Ashok highlights treatment options for patients with EoE aged 12 years and younger and the importance of shared decision-making.
Dr Gutiérrez Junquera discusses ESPGHAN guidelines, clinical data, and long-term management strategies for pediatric EoE.